SARS-CoV-2 tagged posts

Unique experiments involved ‘mini-organs’, animal research, donated human organs, volunteers and patients. Cambridge scientists have identified an off-patent drug that can be repurposed to prevent COVID-19 — and may be capable of protecting against future variants of the virus — in research involving a unique mix of ‘mini-organs’, donor organs, animal studies and patients.

The research, published today in Nature, showed that an existing drug used to treat a type of liver disease is able to ‘lock’ the doorway by which SARS-CoV-2 enters our cells, a receptor on the cell surface known as ACE2...

Paxlovid rebound patient did not show drug resistance or impaired immunity. Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was completed, prompting the Centers for Disease Control and Prevention (CDC) to issue a health advisory on this so-called “COVID-19 rebound.”

In a study published June 20, 2022 in Clinical Infectious Diseases, researchers at University of California San Diego School of Medicine evaluated one such patient and found their symptom relapse was not caused by the development of resistance to the drug or im...

New research reveals Neem-based drugs may help fight future coronavirus variants. Extract from the bark of the Neem tree may help treat and reduce the spread of coronavirus, according to a new study led by scientists at the University of Colorado Anschutz Medical Campus and the Indian Institute of Science Education and Research Kolkata.

The study, reported recently in the journal Virology, shows that components of Neem bark may target a wide range of viral proteins, suggesting its potential as an antiviral agent against emerging variants of coronaviruses (including SARS-CoV-2).

The Neem tree, indigenous to India, has been used for thousands of years for its anti-parasitic, anti-bacterial and antiviral properties...

Cardiovascular care essential part of post-infection care. An in-depth analysis of federal health data indicates that people who have had COVID-19 are at increased risk of developing cardiovascular complications within the first month to a year after infection. Such complications include disruptive heart rhythms, inflammation of the heart, blood clots, stroke, coronary artery disease, heart attack, heart failure or even death.

Such problems occur even among ...